Interim results of the randomized, phase 3 PhALLCON trial indicate ponatinib’s benefit over imatinib in frontline treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), ...
IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 ...
The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Improving the Relative Dose Intensity of Systemic Chemotherapy in a Community-Based Outpatient Cancer Center Patients (age ≥18 years) with at least one CML diagnosis (International Classification of ...
Ibrahim Aldoss, MD, associate professor, City of Hope, explores recent findings on ponatinib as a first-line treatment for Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). We ...
Twelve years after Takeda's Iclusig (ponatinib) earned a restricted FDA approval to treat certain patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), the U.S.
Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to ponatinib with chemotherapy for the treatment of adults with newly ...
Imatinib is an oral targeted therapy used for several cancers and other conditions caused by specific genetic mutations. The medication is approved for: Philadelphia chromosome positive chronic ...
ROCKVILLE, Md. and SUZHOU, China, March 05, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results